-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Initiates Coverage On Immix Biopharma with Outperform Rating, Announces Price Target of $14

Benzinga·02/09/2026 12:39:53
Listen to the news
Mizuho analyst Graig Suvannavejh initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Outperform rating and announces Price Target of $14.